Fundraising Fox

Addimmune

Rockville, US · Founded 2023 · 1 employees on LinkedIn · 1 known investors

Addimmune develops gene therapy treatments for HIV, specifically AGT103-T, a first-in-class functional cure candidate that modifies patient immune cells to recognize and eliminate HIV-infected cells. The company is based in Rockville, Maryland and targets individuals living with HIV.

BiotechDeep TechDigital HealthMedical Devices

Founders & leadership

BW
Barry WellsMD

Investors · 1

Ossian Capital

Competitors · 1

by search overlap
American Gene Technologies35 shared keywordsAmerican Gene Technologies develops gene therapy treatments for serious diseases including HIV, phenylketonuria, and liver cancer, using a proprietary platform approach designed to accelerate drug development and reduce costs.

Companies competing with Addimmune for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Addimmune Prepares to go Public, Initiate Phase Ib HIV Trial | BioBuzzbiobuzz.io · Nov 20244 Biotech Executives Share Strategies Behind Successful Fund Raises | PM360pm360online.com · Dec 2023News - Addimmuneaddimmune.com · Oct 2023Investors - Addimmuneaddimmune.com · Oct 2023Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. IIIfinance.yahoo.com · Aug 2023

Frequently asked questions

What does Addimmune do?
Addimmune develops gene therapy treatments for HIV, specifically AGT103-T, a first-in-class functional cure candidate that modifies patient immune cells to recognize and eliminate HIV-infected cells. The company is based in Rockville, Maryland and targets individuals living with HIV.
Who are Addimmune's investors?
Addimmune's investors include Ossian Capital.
Where is Addimmune headquartered?
Addimmune is headquartered in Rockville, US.